Published Date:2022-05-02 Original Link:https://www.onenessbio.com/en/news_detail163_2.htm No 1 Date of announcement 2022/05/02 Time of announcement  20:10:48 Subject Oneness received the notification by the international CRO on the unblinded data of FB825 Phase 2a study in moderate-to-severe atopic dermatitis in the U.S. To which item it meets paragraph 10 Date of events 2022/05/02 Statement Product:FB825 Anti-CεmX monoclonal antibody...Read More